匯豐研究:下調維他奶(0345.HK)目標價至30港元 評級“持有”
匯豐研究發表報告表示,維他奶(0345.HK)
自去年11月21日公佈中期業績後,股價累跌了3%,現價計2021年預測市盈率39倍,預期2019至2022年盈利增長率為12%,相信該股股價短期內持續波動,同時澳洲持續的乾旱及森林大火可能會對農場的產量產生重大影響,澳洲原材料短缺加劇,並影響其利潤率。
不過報告補充,即使維他奶面對短期經營壓力,但公司在內地的豆奶飲料市場上具有較強的競爭地位,並且可以從長期健康的營養飲食趨勢中受惠。該行下調其2020至2022年度盈利預測8.1%、7.4%及2.7%,主要是反映澳洲業務受到不利天氣的打擊,目標價相應由33港元降至30港元,維持其“
持有
”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.